Close Menu

NEW YORK – Genentech said on Thursday that its Phase III IMpassion131 trial, investigating atezolizumab (Tecentriq) in combination with paclitaxel as a first-line option for metastatic, PD-L1-positive triple-negative breast cancer failed to meet its primary endpoint.

The drug giant didn't report detailed findings but issued a statement that the 650-patient randomized trial failed to demonstrate that the atezolizumab-paclitaxel combination statistically significantly improved progression-free survival compared to just paclitaxel in PD-L1-positive, metastatic TNBC patients. 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.


NTRK fusions are oncogenic drivers in a variety of tumors.

Sponsored by

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Sponsored by

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.


In non-small cell lung cancer (NSCLC), early detection of emerging resistance mutations such as EGFR T790M is important in order to determine the appropriate targeted therapeutic strategy.